<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04480697</url>
  </required_header>
  <id_info>
    <org_study_id>HPG1860-101</org_study_id>
    <nct_id>NCT04480697</nct_id>
  </id_info>
  <brief_title>Study of Safety, Tolerability and PK, PD of HPG1860 in Healthy Subjects</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo Controlled, Single and Multiple Ascending Doses (SAD/MAD) Study Following Oral Administration in Healthy Subjects to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HPG1860</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hepagene (Shanghai) Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hepagene (Shanghai) Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, placebo-controlled, single and multiple ascending dose
      Phase 1study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and
      food effect of HPG1860 orally administered in healthy subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In SAD and MAD studies, all subjects are randomized in a 3:1 ratio. In SAD study , there are
      6 cohorts (8 subjects/cohort) with dose levels of 10mg, 20 mg, 40 mg, 80 mg, 120 mg and 150
      mg respectively. Blood samples will be collected for safety, PK and PD assessments. After the
      completion of Cohort 2 (20 mg) in SAD study, following a 7-day washout period, the same 8
      subjects will receive another single oral dose of 20 mg HPG1860 after a standard high
      fat/high calorie breakfast (the fed condition). PK blood samplings will be collected and Cmax
      and AUC will be used for assessing the food effect. In MAD study, there are 3 cohorts (8
      subjects/cohort) with dose levels of 10mg, 30mg and 90 mg, respectively and dosing regimen is
      once daily for 14 consecutive days. Blood samples will be collected for safety, PK and PD
      assessments.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 10, 2019</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Part 1 SAD: 6 cohorts Part 2 MAD: 3 cohorts</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>After single ascending doses, number of subjects with treatment-emergent adverse events(TEAEs) in the HPG1860 dose-level cohorts</measure>
    <time_frame>Day1-8</time_frame>
    <description>To investigate the safety and tolerability of orally administered SAD of HPG1860 by assessment of AEs, vital signs and clinical laboratory findings.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>After multiple ascending doses, number of subjects with treatment-emergent adverse events(TEAEs) in the HPG1860 dose-level cohorts</measure>
    <time_frame>Day1-21</time_frame>
    <description>To investigate the safety and tolerability of orally administered MAD of HPG1860 by assessment of AEs, vital signs and clinical laboratory findings.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of HPG1860 on Blood Concentration of FGF19 and 7-alpha-hydroxy-4-cholesten-3-one (C4)</measure>
    <time_frame>SAD: Day 1. MAD: Day 1 and Day14</time_frame>
    <description>To assess blood FGF19 and C4 changes vs placebo after orally administered SAD and MAD of HPG1860</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>SAD: up to 48 hours ; MAD: up to 14 days.</time_frame>
    <description>Maximum observed serum concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>SAD: up to 48 hours ; MAD: up to 14 days.</time_frame>
    <description>Time to reach Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUClast</measure>
    <time_frame>SAD: up to 48 hours ; MAD: up to 14 days.</time_frame>
    <description>Area under the curve from the time of dosing to the time of the last measurable concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCinf</measure>
    <time_frame>SAD: up to 48 hours ; MAD: up to 14 days.</time_frame>
    <description>Area under the curve from the time of dosing extrapolated to infinity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL</measure>
    <time_frame>SAD: up to 48 hours; MAD: up to 14 days</time_frame>
    <description>Apparent total body clearance of the drug from plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vd</measure>
    <time_frame>SAD: up to 48 hours; MAD: up to 14 days</time_frame>
    <description>Apparent volume of distribution</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of Food on Cmax of HPG1860</measure>
    <time_frame>up to 48 hours</time_frame>
    <description>To assess the effect of food on a single dose of 20 mg HPG1860 by evaluating Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of Food on AUCinf of HPG1860</measure>
    <time_frame>up to 48 hours</time_frame>
    <description>To assess the effect of food on a single dose of 20 mg HPG1860 by evaluating AUCinf</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of Food on AUC0-24h of HPG1860</measure>
    <time_frame>24 hours</time_frame>
    <description>To assess the effect of food on a single dose of 20 mg HPG1860 by evaluating AUC0-24h</description>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>SAD 10mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single oral dose of 10 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SAD 20mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single oral dose of 20 mg. Food effect will also be assessed at the same dose level.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SAD 40mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single oral dose of 40mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SAD 80 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single oral dose of 80 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SAD 120 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single oral dose of 120 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SAD 150 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single oral dose of 150 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MAD 10mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose regimen is once daily 10 mg for 14 consecutive days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MAD 30mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose regimen is once daily 30 mg for 14 consecutive days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MAD 90 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose regimen is once daily 90mg for 14 consecutive days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HPG1860</intervention_name>
    <description>6 subjects randomized to active compound and 2 subjects randomized to placebo</description>
    <arm_group_label>MAD 10mg</arm_group_label>
    <arm_group_label>MAD 30mg</arm_group_label>
    <arm_group_label>MAD 90 mg</arm_group_label>
    <arm_group_label>SAD 10mg</arm_group_label>
    <arm_group_label>SAD 120 mg</arm_group_label>
    <arm_group_label>SAD 150 mg</arm_group_label>
    <arm_group_label>SAD 20mg</arm_group_label>
    <arm_group_label>SAD 40mg</arm_group_label>
    <arm_group_label>SAD 80 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy subjects aged 18-55 years old (inclusive), male or female

          2. Females must be of non-childbearing potential

          3. Have a body mass index (BMI) between 18.0 and 32.0 kg/m2 (inclusive) and weigh at
             least 50 kg at time of Screening

        Exclusion Criteria:

          1. Clinically significant history of gastrointestinal, cardiovascular, musculoskeletal,
             endocrine, hematologic, psychiatric, renal, hepatic, bronchopulmonary, neurologic,
             immunologic, lipid metabolism disorders, or drug hypersensitivity as determined by the
             Investigator

          2. Taken an investigational drug within 3 months or 5 half-live, whichever is longer from
             the Screening date

          3. Any liver function panel analyte (LFT) value &gt; upper limits of normal reference range

          4. Positive blood screen for human immunodeficiency virus (HIV), hepatitis B core (IgG
             and IgM) and surface antigen (HBsAg), Hepatitis A antibody (IgM), hepatitis C antibody
             (IgG), or hepatitis E (IgG and IgM) at Screening

          5. Any condition or finding that in the opinion of the Principal Investigator or designee
             would put the subject or study conduct at risk if the subject were to participate in
             the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Dr. Xu</last_name>
    <phone>01186-21-61215841</phone>
    <email>Michael.Xu@hepagene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Pharmaron CPC InC</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paolo DePetillo, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 14, 2020</study_first_submitted>
  <study_first_submitted_qc>July 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 21, 2020</study_first_posted>
  <last_update_submitted>July 17, 2020</last_update_submitted>
  <last_update_submitted_qc>July 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

